Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.

@article{Brottier1990TherapeuticVO,
  title={Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.},
  author={L Brottier and J. L. Barat and Christian Combe and B. Boussens and J. -C. Bonnet and Henri Bricaud},
  journal={European heart journal},
  year={1990},
  volume={11 3},
  pages={207-12}
}
Trimetazidine (TMZ) has been shown to have anti-ischaemic properties improving exercise tolerance without haemodynamic effects. A 6-month double-blind placebo-controlled study was carried out in 20 patients, mean age 59 +/- 6 years, to examine the benefit of adding 60 mg of TMZ vs placebo to the classical therapy, excluding those previously treated with calcium-antagonists, conversion enzyme inhibitors, vasodilators and antiplatelet agents. All patients had severe ischaemic cardiomyopathy… CONTINUE READING